High Interest Rates Threaten Global Innovation Momentum
The latest findings from the UN’s World Intellectual Property Organization (WIPO) reveal a shifting landscape for global innovation funding. While 2022 saw record-breaking corporate and government spending on research and development—particularly in artificial intelligence, biotechnology, and other advanced sectors—the flow of venture capital that often propels these ideas toward market readiness has sharply contracted. According to WIPO, the global value of venture capital funding fell by 40 percent in 2022 compared to the previous year, a downturn that has persisted into 2023. In the first half of this year alone, venture capital investment dropped a further 47 percent relative to the same period in 2022.
“There has been a drop in the investment environment,” WIPO Director General Daren Tang stated during a virtual briefing. “Venture capital funding is becoming more and more scarce.” This scarcity follows a surge in 2021, when pandemic-driven urgency fueled unprecedented investment in emerging technologies and regions traditionally outside the main innovation hubs. That surge has now given way to what co-author of the report Sacha Wunsch-Vincent described as “only the tip of the iceberg” in terms of the downturn.
The report attributes much of the contraction to broader macroeconomic pressures. Wunsch-Vincent pointed to “a harsher investment conditions,” noting that high interest rates have fundamentally altered the cost of capital. “Borrowing isn’t free anymore. It’s really the end of cheap money,” he said. Combined with slow post-pandemic economic recoveries and ongoing geopolitical tensions, these financial headwinds pose significant risks to the future trajectory of innovation.
Yet the data presents a nuanced picture. Corporate R&D spending reached an unprecedented $1.1 trillion in 2022, and preliminary figures suggest government R&D budgets also rose in real terms. Patent activity continued its upward trend, and while the total value of venture capital fell, the number of deals actually increased. This uptick in deal volume was driven in part by intense activity in artificial intelligence, where information and communication technology firms are “almost in an arms race for more spending on AI,” according to Wunsch-Vincent. Pharma, biotech, and construction sectors also saw heightened investment, while industries that cut back during the pandemic—such as automotive manufacturing—have rebounded.
The Global Innovation Index 2023, released alongside the funding analysis, underscores another transformation: the diversification of the innovation economy. “It is getting more diverse, there are more engines of innovation around the world,” Tang observed. Switzerland retained its position at the top of the rankings for the 13th consecutive year, followed by Sweden in second place and the United States in third. The top ten remains dominated by Western nations, with Singapore in fifth and South Korea in tenth as notable exceptions.
China, while slipping slightly from 11th to 12th place this year, has made remarkable progress over the past decade, climbing from 35th. Other middle-income countries such as Turkey, India, and Iran have also advanced rapidly. Since the onset of the pandemic, Mauritius, Indonesia, Saudi Arabia, Brazil, and Pakistan have posted some of the most significant gains in innovation performance.
One notable regional insight from WIPO’s data is that Africa was the only continent where the value of venture capital funding did not decline in 2022. Wunsch-Vincent highlighted this resilience, noting that despite the global contraction, investment remained geographically distributed rather than reverting solely to traditional innovation centers.
For sectors reliant on sustained funding—such as aerospace, robotics, and advanced materials—the interplay between rising R&D expenditures and shrinking venture capital flows presents both opportunities and challenges. The surge in corporate and governmental research budgets suggests that foundational innovation work continues at pace, but the reduced availability of risk capital may slow the transition from laboratory breakthroughs to market-ready technologies.
